About Us

Cell and Gene Therapies to Restore Liver Function & Regenerate the Liver

We are pioneering the novel application of cell and gene therapies to reverse liver disease progression and restore liver function for patients with severe liver disease. Applying these technologies to large patient populations represents a dramatic evolution for cell and gene therapies. To date, these technologies have only been used to stimulate or block a specific activity and to treat a small number of patients.

Liver diseases remain one of the most underserved areas of modern medicine. Despite progress with a few diseases, by and large most liver diseases – both chronic and acute – are not effectively addressed.

For thousands of patients with severe liver diseases, liver transplant is the only option. Those fortunate enough to receive a donor liver face a difficult operation, months of recovery, and a lifetime of immuno-suppressive drugs. Nearly forty thousand cirrhosis patients die annually in the US – this is expected to double by 2030.

A Revolutionary Approach

We are pioneering the novel application of cell and gene therapies to reverse liver disease progression and restore liver function for millions of patients. Applying these technologies to large patient populations represents a dramatic evolution for cell and gene therapies. To date, these technologies have only been used to stimulate or block a specific activity and to treat a small number of patients.

Our Lead Programs

Our lead programs harness the natural regenerative properties of the liver, targeting a spectrum of severe acute and chronic liver diseases, including ‘off the shelf’ hepatocyte replacement cell therapies and hepatocyte-directed gene therapies to restore normal liver function.

Leadership Team

photo of Stanley
Stanley Hollenbach, J.D.
SVP, Pharmacology
Michael Holmes, Ph.D.
Chief Scientific Officer
Ronald Park, M.D., M.B.A.
Chief Executive Officer
Glenn Pierce, M.D., Ph.D.
Interim Chief Medical Officer
Deidre Roniger
SVP Corporate Development
Nancy Shulman, MD
VP of Translational Medicine
Alan Smith, Ph.D.
Chief Technology Officer
photo of Grady Snyder
Grady Snyder
Chief of Staff, Sr. Director of Operations
photo of Ran, woman smiling into the camera, on light background
Ran Xiao, CFA
VP Finance, Corporate Controller
Ronald Park, M.D., M.B.A.
Chief Executive Officer
Asit Parikh, M.D., Ph.D.
Takeda Pharmaceuticals
Charles Homcy, M.D.
Third Rock Ventures
Jeff Tong, Ph.D.
Third Rock Ventures
Jennifer Cook
Independent Board Director
Holger Willenbring, M.D., Ph.D.
University of California, San Francisco
Juan Carlos Izpisua Belmonte, Ph.D.
Salk Institute
Markus Grompe, M.D.
Oregon Health and Sciences University
Martin Burke, M.D., Ph.D.
University of Illinois at Urbana-Champaign

Building an Ambytious Company

Founding Investors
Third Rock Ventures & Takeda
$140 Million
Starting Capital
Launched In August 2018
One Goal:
A World Without Liver Transplants
70+
Ambysians
Headquarters
The Cove at Oyster Point
South San Francisco
Lead Programs
"Off The Shelf"
Hepatocyte Replacement Cell Therapies and Hepatocyte-Directed Gene Therapies
Top